Covid19 Clinical Trial
Official title:
Clinical Evaluation of Ventilator Innovation Product in Colombia in the SARS Pandemic Covid 19, Unisabana Herons - A Cohort Study - Phase 1
The objective of this study is to evaluate the efficacy and safety of the Unisabana-Herons
invasive mechanical ventilator designed to provide the basic ventilatory support necessary to
preserve the life of patients with respiratory failure and indication of mechanical
ventilation, especially for those who suffer from acute respiratory distress syndrome (ARDS)
when conventional commercial invasive ventilators are not available in the context of the
health emergency due to the COVID-19 epidemic.
The Unisabana-Herons ventilator allows to precisely configure the respiratory rate, tidal
volume (or inspired air volume), inspiratory time, the inspiration: expiration ratio, the
positive pressure at the end of expiration (PEEP), the inspired fraction of oxygen and
inspiratory air flow, parameters that allow managing the respiratory failure associated with
COVID-19. The ventilator also monitors peak inspiratory pressures (PIP), mean, PEEP, plateau,
and graphs in real time the pressure-time, volume-time, flow-time curves, which allows
detecting when one of these is at levels dangerous to induce ventilator trauma (barotrauma
and volutrauma) and thus ensure effective and safe ventilation, so as to avoid
ventilator-induced lung injury.
The Unisabana-Herons ventilator is an invasive mechanical ventilator that works on the same
principles of invasive positive pressure mechanical ventilators that have existed for 80
years. Although the effectiveness of ventilatory assistance in saving human lives was known
since biblical times, the first mechanical ventilators only appeared in 1800 and it was in
1900 when the first positive pressure ventilators were manufactured, which have a turning
point in 1940 as a result of the polio epidemic, when invasive positive pressure mechanical
ventilators were developed that could be used massively and have evolved to current models.
These positive pressure fans completely replaced the first negative pressure models, have
abundant support in the scientific literature, and are the most commonly used today.
Since the beginning of the COVID-19 epidemic in Colombia, the University of La Sabana, a
multidisciplinary team in order to find solutions to deal with the disease, and its first
project, consisted in the design and manufacture of an invasive mechanical ventilator
(Ventilator Unisabana-Herons) able to supply the basic ventilatory needs of the patient with
severe respiratory failure due to COVID-19 at the time when the installed capacity of classic
commercial mechanical ventilators is exhausted. The Unisabana-Herons ventilator was built
based on those recommended by INVIMA, the MHRA (UK Medicines and Devices Regulatory Agency)
and the FDA, to provide efficient and safe volume controlled ventilation to patients with
indications. of mechanical ventilation for respiratory failure according to the ventilatory
modes already affected that have strong scientific evidence.
This study seeks to evaluate the effectiveness, usability and safety of the Unisabana-Herons
ventilator for the management of patients with an indication for invasive mechanical
ventilatory support, admitted to level III and IV university hospitals with Intensive Care
services enabled through a cohort study of 5 patients with a 24-hour follow-up.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |